Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

Phase 2

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Photodynamic therapy (PDT)
Drug: Vitamin D3

Registration Number: NCT04140292

Lead Sponsor: Case Comprehensive Cancer Center

Brief Summary: This study is open to individuals with Actinic Keratoses (skin lesions that have the potential to turn into skin cancer), who are receiving photodynamic therapy (PDT) as part of their clinical care. The purpose of this study is to test and demonstrate that vitamin D pre-treatment can enhance PDT efficacy in the treatment of Actinic Keratoses.

Participants will be asked to take vitamin D supplements prior to their standard of care PDT treatment.

Participation in the research will last about 3-4 months.

Detailed Description: The primary objective of this study is to determine whether acute supplementation (neoadjuvant Vitamin D3), adjusted according to baseline Vitamin D status, can improve the clinical PDT response relative to participants receiving PDT alone

The secondary objective of this study is to determine whether gene polymorphisms in VDR and CYP27B1 are predictive for the degree of responsiveness to Vitamin D as a neoadjuvant for PDT.

This study is a non-randomized interventional trial, in which the study group will be compared to a baseline cohort of patients from a previous study who received the same regimen of PDT, but without any Vit D. It is anticipated that 30 participants will be involved in this study.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 75

Inclusion Criteria

Actinic keratoses in sufficient numbers (>10) to warrant PDT therapy in the clinic
Able to understand and willing to sign a written informed consent document
Female subjects must not become pregnant during the study:
- The effects of 5-aminolevulinic acid (LevulanTM) on the human fetus are unknown. For this reason, women of child-bearing potential must agree to use contraception (double barrier method of birth control or abstinence) prior to study entry, and throughout study participation. Should a woman become pregnant or suspect that she is pregnant while she is participating in this study, she should inform the treating physician immediately.

Exclusion Criteria

Pregnant or nursing.
At risk for hypercalcemia (renal disease, sarcoidosis, etc.)
Using topical retinoids, since these can exacerbate the post-PDT erythema reaction.
Using any topical treatment on their AKs; must stop at least one month prior.
Currently undergoing treatment for other cancers with medical or radiation therapy.
Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material.
Patients with history of a photosensitivity disease, such as porphyria cutanea tarda.
Currently participating in another clinical trial.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Vitamin D3 + Photodynamic therapy (PDT)	Photodynamic therapy (PDT)	Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.
Vitamin D3 + Photodynamic therapy (PDT)	Vitamin D3	Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level. They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.

Primary Outcome Measures

Name	Time	Method
Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months	3 months after treatment	Clinical PDT response as measured by the percent change of AK lesions 3 months after treatment Baseline vitamin D (calcidiol) level will be taken for each patient.

Secondary Outcome Measures

Name	Time	Method
Correlation Between Vitamin D Receptor (VDR) Polymorphisms and Percent Reduction in AK	3 months after treatment	Whether gene polymorphisms in VDR and CYP27B1 are predictive for the degree of responsiveness (as measured by percent reduction in AK) to Vitamin D as a neoadjuvant for PDT.
Number of Participants Reporting 1 or Higher on the Pain Scale	During treatment (at the 5 min mark), and again immediately afterwards.	Pain scale recorded on a 0-to-10 visual/analog scale, with higher scores mean more pain; 0 is no pain, 10 is "the worst pain imaginable". Number of participants receiving treatment that reported a pain level greater than 1.
Tolerability as Measured by Participants' Symptom Score Sheets	1 week after treatment	Participants are asked to recall the symptoms they experienced during the week following PDT. The study physician asks them whether they had experienced each of the following 13 symptoms (YES/NO), and positive (YES) answers were summed to create a Side Effects Score (SES). The maximum and minimum possible values are 13 and 0 respectively, with a higher score correlating to poorer participant outcomes. The 13 possible side effects were: pain, erythema, scabbing, blistering, erosions, edema, warmth, exfoliation, discharge, hemorrhage, tightness, hyperpigmentation, hypopigmentation.
Accumulation of Protoporphyrin IX (PpIX) Within AK	3 months after treatment	Accumulation of protoporphyrin IX (PpIX) within AK PpIX accumulation in areas of both actinic damage and normal skin will be measured with a fluorescence dosimeter. The level of calcidiol, a clinically accepted marker of vitamin D status, will be measured in each patient to see if supplementation with 10,000 IU of Vitamin D increase the accumulation